Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022
In December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, became predominant in the United States. Subsequently, national COVID-19 case rates peaked at their highest recorded levels.* Traditional methods of disease surveillance do not capture all COVID-19 cases...
Saved in:
Published in | MMWR. Morbidity and mortality weekly report Vol. 71; no. 17; pp. 606 - 608 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article Newsletter |
Language | English |
Published |
United States
U.S. Government Printing Office
29.04.2022
U.S. Center for Disease Control Centers for Disease Control and Prevention |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, became predominant in the United States. Subsequently, national COVID-19 case rates peaked at their highest recorded levels.* Traditional methods of disease surveillance do not capture all COVID-19 cases because some are asymptomatic, not diagnosed, or not reported; therefore, the proportion of the population with SARS-CoV-2 antibodies (i.e., seroprevalence) can improve understanding of population-level incidence of COVID-19. This report uses data from CDC's national commercial laboratory seroprevalence study and the 2018 American Community Survey to examine U.S. trends in infection-induced SARS-CoV-2 seroprevalence during September 2021-February 2022, by age group. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0149-2195 1545-861X |
DOI: | 10.15585/mmwr.mm7117e3 |